Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01
Publication date: Available online 26 October 2026 Source: Annals of Oncology Author(s): B. Xu, Y. Yin, Y. Fan, Q. Ouyang, L. Song, X. Wang, W. Li, M. Li, X. Yan, S. Wang, T. Sun, Y. Teng, X. Tang, Z. Tong, Z. Sun, G. Liu, Y. Diao, X. Jin, J. Ge
Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426068808?dgcid=rss_sd_all
Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426068808?dgcid=rss_sd_all
“Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01.” Annals of Oncology.
@article{article36100,
title = {Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426068808?dgcid=rss_sd_all}
}